Principal investigator: Roni Nielsen (Dept. of Cardiology)
Dept. of Nuclear Medicine & PET Centre: Hendrik Johannes Harms, Lars Poulsen Tolbod, Jens Sørensen, Peter Iversen, Kirsten Bouchelouche, Jørgen Frøkiær
Background: In the LIVE study, the effect of the Glucagon-like peptide -1 (GLP-1) receptor agonist Liraglutide on left ventricle function in heart failure patients is examined. Liraglutide is one of the newest anti-diabetic medications. GLP-1 receptor agonists have also been shown to protect the heart during acute ischemia. However, the effect in patients with stable heart failure has not previously been examined.
Objectives: This sub-study of the LIVE study examines the effect of 24 weeks of Liraglutide treatment on myocardial glucose uptake (18F-FDG PET) and perfusion (15O-water PET) in heart failure patients without known diabetes.